Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook

More articles from Clinical (Endocrine/Neuroendocrine)

  • You have access
    First-in-human study of novel SSTR antagonist 177Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: dosimetry, safety and efficacy
    Richard P. Baum, Jingjing Zhang, Christiane Schuchardt, Dirk Mueller and Helmut Maecke
    Journal of Nuclear Medicine March 5, 2021, jnumed.120.258889; DOI: https://doi.org/10.2967/jnumed.120.258889
  • Open Access
    Dual Positron Emission Tomography imaging in bronchial neuroendocrine neoplasms (NENs): The NETPET score as a prognostic biomarker
    David L Chan, Gary A Ulaner, David A. Pattison, David Wyld, Rahul Ladwa, Julian Kirchner, Bob T Li, W. Victoria Lai, Nick Pavlakis, PAUL J ROACH and Dale L. Bailey
    Journal of Nuclear Medicine February 12, 2021, jnumed.120.257659; DOI: https://doi.org/10.2967/jnumed.120.257659
  • You have access
    Assessment and comparison of fluorocholine PET and sestamibi scans in identifying parathyroid adenomas: a meta-analysis
    Julia Whitman, Isabel E Allen, Emily K. Bergsland, Insoo A. Suh and Thomas A. Hope
    Journal of Nuclear Medicine January 15, 2021, jnumed.120.257303; DOI: https://doi.org/10.2967/jnumed.120.257303
  • You have access
    Imaging of the glucagon receptor in subjects with type 2 diabetes
    Olof Eriksson, Irina Velikyan, Torsten Haack, Martin Bossart, Iina Laitinen, Philip J Larsen, Jan-Erik Berglund, Gunnar Antoni, Lars Johansson, Stefan Pierrou, Joachim Tillner and Michael Wagner
    Journal of Nuclear Medicine October 23, 2020, jnumed.118.213306; DOI: https://doi.org/10.2967/jnumed.118.213306
  • You have access
    18F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy: a prospective 10-year follow-up study of 166 patients
    Tina Binderup, Ulrich Knigge, Camilla Bardram Johnbeck, Annika Loft, Anne Kiil Berthelsen, Peter Oturai, Jann Mortensen, Birgitte Federspiel, Seppo W Langer and Andreas Kjaer
    Journal of Nuclear Medicine October 16, 2020, jnumed.120.244798; DOI: https://doi.org/10.2967/jnumed.120.244798
  • You have access
    Repeatability of Radiomic Features of Brown Adipose Tissue
    Aria Nazeri, John P Crandall, Tyler J Fraum and Richard L. Wahl
    Journal of Nuclear Medicine October 9, 2020, jnumed.120.248674; DOI: https://doi.org/10.2967/jnumed.120.248674
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire